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CD137 differentially regulates innate and adaptive
immunity against Mycobacterium tuberculosis
Darı ´oAF e r n a ´ndez Do Porto1, Javier O Jurado1, Virginia Pasquinelli1, Ivana B Alvarez1, Romina H Aspera1,
Rosa M Musella2 and Vero ´nica E Garcı ´a1
Protective immunity against Mycobacterium tuberculosis is primarily mediated by the interaction of antigen-speciﬁc T cells and
antigen presenting cells, which often depends on the interplay of cytokines produced by these cells. Costimulatory signals
represent a complex network of receptor–ligand interactions that qualitatively and quantitatively inﬂuence immune responses.
Thus, here we investigated the function of CD137 and CD137L, molecules known to have a central role in immune regulation,
during human tuberculosis (TB). We demonstrated that M. tuberculosis antigen stimulation increased both CD137 and CD137L
expression on monocytes and NK cells from TB patients and healthy donors, but only up-regulated CD137 on T lymphocytes.
Blockage of the CD137 pathway enhanced the levels of interferon (IFN)-c and tumor necrosis factor (TNF)-a produced by
monocytes and NK against M. tuberculosis. In contrast, CD137 blockage signiﬁcantly decreased the speciﬁc degranulation
of CD8+ T cells and the percentage of speciﬁc IFN-c and TNF-a producing lymphocytes against the pathogen. Furthermore,
inhibition of the CD137 pathway markedly increased T-cell apoptosis. Taken together, our results demonstrate that
CD137:CD137L interactions regulate the innate and adaptive immune response of the host against M. tuberculosis.
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Tuberculosis (TB) remains an enormous global health problem despite
current drug treatment. The disease causes nearly 9 million new cases
and 2 million deaths annually worldwide, and is among the most
common causes of morbidity and mortality in patients with HIV
infection. Bacillus Calmette-Gue ´rin, the only available vaccine, is of
variable efﬁcacy, especially in TB-endemic regions, such as Argentina.
Development of a more effective vaccine depends on a better under-
standing of the human immune response to this pathogen. Although
protective immunological mechanisms against Mycobacterium
tuberculosis are not fully understood, resistance to mycobacterial
infections is primarily mediated by the interaction of antigen-speciﬁc
T cells and macrophages.1,2 This interaction is often dependent on the
interplay of cytokines produced by these cells. Even though a broad
spectrum of cytokines may contribute to protection, a type 1 response,
dominated by interferon (IFN)-g secretion, is considered a principal
mediator of protective immunity against M. tuberculosis.2,3 Besides,
CD8+ T lymphocytes also contribute to protection by lysing infected
cells.4 In addition, innate immune response-related pro-inﬂammatory
cytokines, interleukin-6, interleukin-12, tumor necrosis factor
(TNF)-a, initiate events that limit mycobacterial growth by recruiting
monocytes into the lesions and activating them.5 In particular,
TNF-a, mainly secreted by activated macrophages, contributes to
anti-tubercular action and limits disease pathology.1 Therefore, it is
considered of vast interest to investigate the regulation of cytokine
responses during active TB.
Several signaling proteins contribute to the active up- or down-
regulation during the priming of a T cell,6 modulating the level and
pattern of cytokines produced by those cells upon antigen stimulation.
For example, during the immune response of the host against
M. tuberculosis, we demonstrated that SLAM (signaling lymphocytic
activation molecule) and ICOS (inducible costimulator) enhanced
IFN-g secretion,7,8 whereas the SAP (SLAM-associated protein),
CD31 and PD-1 (programmed cell death 1) interfered with Th1
responses.7,9,10 Another signaling molecule that participates in the
regulation of T-cell effector functions is the receptor CD137 (4-1BB), a
member of the TNF receptor (TNFR) superfamily that can have a
costimulatory role for T-cell immunity upon binding with its ligand
CD137L.11,12 In particular, it was reported that CD137:CD137L inter-
actions boost CD8 T-cell responses, although the expression proﬁle
of CD137 is now known to be quite broad, being present or induced
on various types of immune cells, and not solely restricted within
T-lineage cells.13,14 Moreover, during persistent infection, CD137
expression can be prolonged.14 In addition, CD137 may be an effective
costimulator for enhancing T-cell responses in chronically infected
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www.nature.com/icbindividuals,14 promoting Th1 cytokine responses.14 Therefore, our
speciﬁc aim was to elucidate whether CD137 and its ligand partici-
pated in the regulation of cell-mediated immune responses to
M. tuberculosis.
RESULTS
M. tuberculosis increased the expression of CD137 and CD137L on
cells from the innate and adaptive immune response
The timing of CD137/CD137L interactions and their effects on T cells
may depend on the availability and induction of the ligand and the
receptor during a particular immune response.14
Therefore, we considered important to analyze the expression
proﬁle of CD137 and CD137L on cells from the innate and adaptive
immune response during active TB. We ﬁrst investigated CD137 and
CD137L expression on monocytes and NK cells from TB patients and
healthy donors (HD) upon M. tuberculosis antigen (M.tb Ag) stimula-
tion. Although, it is controversial whether CD137 is expressed on
human monocytes15,16 ON (overnight) M.tb Ag stimulation induced
CD137 expression on CD14+ c e l l sf r o mT Bp a t i e n t sa n dH D( F i g u r e1 a ,
left panel). Besides, CD137L expression was signiﬁcantly augmented on
monocytes after M.tb Ag stimulation (Figure 1a, right panel). Moreover,
signiﬁcant percentages of CD137 and CD137L were also detected on
CD56bright N Kc e l l so fb o t hg r o u p so fi n d i v i d u a l s( F i g u r e1 b ) .
We then analyzed the levels of CD137 and CD137L on lymphocytes.
Minimal levels of CD137 were detected on resting T cells from TB
patients (data not shown), as previously reported in human T cells.17
However, 5 days of M.tb Ag stimulation signiﬁcantly increased CD137
expression, with higher levels of the receptor on CD3+ T cells from TB
patients as compared with HD (Figure 1c, left panel). In contrast,
no detectable levels of CD137L could be detected on T lymphocytes
(Figure 1c, right panel).
CD137:CD137L pathway modulated the cytokine
microenvironment during human TB
Cytokines display a crucial role during the immune response of
the host against M. tuberculosis. Thus, we investigated the potential
function of CD137:CD137L interactions on the modulation of cyto-
kine production by cells from the innate and adaptive immune
response. To do this, we analyzed two central cytokines in TB:
TNF-a and IFN-g. Our results demonstrated that blockage of
CD137 pathway signiﬁcantly augmented both TNF-a and IFN-g
production by TB patients and HD after 16h (ON) of M.tb Ag
stimulation (Figure 2). In contrast, CD137 or CD137L blockade
after PMA stimulation inhibited IFN-g and TNF-a secretion by
both groups of individuals (data not shown). Interestingly, after 2 and
5d a y so fM.tb Ag stimulation, blockage of CD137 increased TNF-a
production but decreased IFN-g secretion (Figure 2). Similar results
were obtained when CD137L was blocked (data not shown).
Our results indicate that CD137:CD137L interactions might induce
distinct effects on cytokine secretion, probably by different cell types
during the initial and later phases of the immune response. To further
investigate this possibility, we analyzed the production of cytokines at
Figure 1 M. tuberculosis increased the expression of CD137 and CD137L
on cells from the innate and adaptive immune response. PBMC from TB
patients and HD were stimulated±M.tb Ag for 16h (a), 24h (b)o r5d a y s
(c). CD137 (left panel) and CD137L (right panel) expression was
determined by ﬂow cytometry. The cytometric analysis was performed ﬁrst
gating on monocytes by light scatter and then by gating on CD14+ cells (a),
or ﬁrst gating on lymphocytes by light scatter, and then on CD3 CD56bright
for NK cells (b) or on CD3+ for T lymphocytes (c). Each bar represents the
mean±s.e.m. from each group (seven individuals per group). ***Po0.001;
**Po0.01; *Po0.05 Wilcoxon rank sum test. wPo0.05 Mann–Whitney
U-test.
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Immunology and Cell Biologythe single-cell level. As shown in Figures 3a and b, ON stimulation
with M.tb Ag signiﬁcantly increased CD14+TNF-a+ and CD14+IFN-g+
cells. Interestingly, CD137 blockade strikingly augmented the percen-
tage of speciﬁc CD14+TNF-a+ and CD14+IFN-g+ producing cells in
both groups of individuals (Figures 3a and b). Furthermore, blockage
of CD137:CD137L pathway also augmented CD3 CD56bright TNF-a
producing NK cells against M.tb Ag (Figure 3c). Remarkably, IFN-g
production by NK cells was also augmented after blocking CD137
(Figure 3d). Thus, CD137:CD137L pathway operates diminishing the
secretion of TNF-a and IFN-g by monocytes and NK cells. We then
hypothesized that early during M. tuberculosis infection, interactions
between CD137 and CD137L on cells from the innate immune
response would regulate the secretion of TNF-a and IFN-g, likely by
preventing cytokine over production that might cause tissue damage,
but allowing the presence of enough levels of cytokines to control the
infection.
We also investigated whether CD137:CD137L interactions regulated
the percentage of IFN-g and/or TNF-a producing lymphocytes. Thus,
peripheral blood mononuclear cells (PBMC) from TB patients and
control individuals were stimulated with M.tb Ag±anti-CD137
monoclonal antibody (mAb) and the percentage of IFN-g and
TNF-a producing cells were determined. As shown in Figure 4, TB
patients and HD produced signiﬁcant numbers of CD3+IFN-g+ and
CD3+TNF-a+ T cells against M.tb Ag, and CD137 blockade strikingly
diminished the percentage of speciﬁc IFN-g/TNF-a producing lym-
phocytes. Considering that the production of IFN-g by T lymphocytes
is crucial to control M. tuberculosis infection, we also investigated
the effect of blocking CD137 on IFN-g secretion by CD4+ and
CD8+ T cells. Our data demonstrated that CD137:CD137L inter-
actions enhance IFN-g production from both CD4+ and CD8+ T cells
(Figure 4c). Together, our results demonstrated that the CD137:
CD137L pathway might differently regulate cytokine production
during innate and adaptive immune response against M. tuberculosis.
CD137:CD137L interactions regulated the survival and lytic
degranulation of T lymphocytes in TB
We next evaluated whether signaling through CD137 might modulate
other effector functions of T cells in TB. Then, we ﬁrst analyzed the
role of CD137:CD137L interactions on CD8+ T-cell-speciﬁc lytic
degranulation against M.tb Ag. We observed that blockage of CD137
signiﬁcantly decreased the percentage of CD3+CD8+ T cells from TB
patients expressing CD107a/b (Figures 5a and b). CD8+ T cells from
HD showed a weak lytic degranulation against M.tb Ag, with no
signiﬁcant variations after the CD137:CD137L pathway blockade
(Figure 5a). Therefore, our data indicate that CD137 signaling
up-regulates the cell degranulation of CD3+CD8+ lymphocytes after
M.tb Ag stimulation.
Since its discovery, the studies that followed established CD137
as a potent costimulatory molecule. Thus, signaling through CD137
was demonstrated to induce T-cell expansion, up-regulation of anti-
apoptotic genes and prevention of activation-induced cell death.17 So,
we next studied the role of CD137 signaling on cell proliferation. As
shown in Figure 6a, PBMC from HD displayed higher proliferation
against M.tb Ag as compared with TB patients. Moreover, the blockage
of CD137 or CD137L signiﬁcantly decreased the speciﬁc proliferation
against M.tb Ag in both group of individuals (Figure 6a), clearly
demonstrating that CD137:CD137L interactions induced M.tb
Ag-speciﬁc cell expansion. Then, we studied the potential role of the
CD137:CD137L pathway on T-cell apoptosis. Our results conﬁrmed
that M.tb Ag stimulation led to apoptosis of T lymphocytes from TB
Figure 2 Role of the CD137:CD137L pathway on the cytokine microenvironment during human TB. PBMC from TB patients and HD were stimulated with
M.tb Ag, in the presence or absence of CD137 blocking mAb. After 16h (ON), 2 or 5 days cell-free supernatants were collected and assayed for TNF-a
(a)a n dI F N - g (b) production by ELISA. The mean±s.e.m. (15 individuals per group) of IFN-g and TNF-a secretion levels is shown for each time. **Po0.01;
*Po0.05 Wilcoxon rank sum test.
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Immunology and Cell Biologypatients (Figures 6b and c), as measured by Annexin V/PI (propidium
iodide) staining, in line with previous reports.18 Furthermore, block-
age of CD137 (or CD137L) signiﬁcantly augmented the percentage
of apoptotic M.tb Ag-stimulated CD3+ T cells (Figures 6b and c).
Moreover, as described in Figure 6c, the CD137:CD137L pathway
inhibited apoptosis of both CD4+ and CD8+ cells in comparable way,
indicating that signaling through CD137 prevents programmed cell
death of speciﬁc T cells during active disease. Since TNF-a is a pro-
apoptotic soluble factor, these results are in correlation with our data
demonstrating that CD137 pathway diminished TNF-a secretion.
DISCUSSION
Costimulatory signals do not only provide an ‘on or off’ switch but
rather represent a complex network of receptor–ligand interactions
that qualitatively and quantitatively inﬂuence immune responses and
affect all its major participants including effector lymphocytes and
dendritic cells.19 Among TNFR superfamily members, CD137 has
been shown to display diverse roles in adaptive and innate immune
responses, but little is known about its function during the regulatory
pathways that contribute to persistence of intracellular bacteria.20
Therefore, in this work we investigated the role of the CD137:
CD137L pathway during chronic human TB.
CD137 participates at different stages and inﬂuences distinct aspects
of the immune response, likely due to the differential expression of
receptor and ligand relative to other costimulatory molecules.14 With
non-replicating Ag, CD137 is expressed only transiently on T cells
in vivo.21 However, when Ag persists, CD137 expression can be
prolonged.22–24 Thus, the effects of CD137 pathway on immune
cells may depend in part on its expression pattern in the particular
model studied. Our results showed that stimulation with M.tb Ag
markedly increased the levels of CD137 and CD137L on monocytes.
Accordingly, it was reported that various stimuli, including innate and
adaptive signals, can promote the expression of CD137L or other
TNFR ligands on antigen presenting cells.25 Besides, although the
expression of CD137 on activated human NK cells has been recently
described in patients with acute myeloid leukemia,26 our data demon-
strated that M.tb Ag increases both CD137 and CD137L expression on
CD56bright NK cells. These data are in line with our previous results on
the expression and role of PD-1 on NK cells in TB.27 Moreover, after 5
days of M.tb Ag stimulation, a signiﬁcant augment of CD137 on T
lymphocytes was also detected.
We showed that M.tb Ag induced differential expression of CD137
and CD137L on cells from the innate and adaptive immune response.
Thus, we hypothesized that CD137 and CD137L might participate in
the modulation of the host immunity against this pathogen. When we
Figure 3 Effect of CD137:CD137L pathway on the production of cytokines
by monocytes and NK cells. (a, b) PBMC from TB patients and HD were
stimulated with M.tb Ag in the presence or absence of blocking anti-
CD137mAb. After 16h, the intracellular expression of TNF-a (a)a n d
IFN-g (b) was determined by ﬂow cytometry, ﬁrst gating on monocytes by
light scatter, then by gating on CD14+ cells. Each bar represents the
mean±s.e.m. of the percentage of CD14+cytokine+ cells for each group
(11 individuals per group). (c, d); PBMC from TB patients and HD were
stimulated with M.tb Ag for 24h in the presence or absence of blocking
anti-CD137mAb and intracellular TNF-a (c) and IFN-g (d) expression on
CD56bright NK cells were determined by ﬂow cytometry by ﬁrst gating on
lymphocytes by light scatter, then by gating on CD3  cells and ﬁnally on
CD56bright NK cells. Each bar represents the mean±s.e.m. (10 individuals).
**Po0.01; *Po0.05 Wilcoxon rank sum test. wPo0.05 Mann–Whitney
U-test.
Figure 4 Effect of CD137:CD137L pathway on the production of cytokines
by T lymphocytes. PBMC from TB patients and HD were stimulated
with M.tb Ag for 4 days in the presence or absence of anti-CD137 blocking
mAb. (a, b) Intracellular TNF-a (a)a n dI F N - g (b) expression were deter-
mined by ﬂow cytometry on T cells. Each bar represents the mean±s.e.m.
(17 individuals per group). **Po0.005; *Po0.05 Wilcoxon rank sum test.
wPo0.05 Mann–Whitney U-test. (c) The number of IFN-g producing cells
was also determined on CD3+CD4+ and CD3+CD8+ cells. Lymphocytes were
gated based on their light scatter proﬁle and gated further based on CD3+
and CD4+ or CD8+ expression. Data of nine independent experiments are
shown (mean±s.e.m.). P-values were calculated using the Wilcoxon rank
sum test by comparing the mean of IFN-g producing T cells cultured with
media versus M.tb Ag and cells cultured with M.tb Ag versus M.tb Ag +
a-CD137.
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Immunology and Cell Biologyblocked the CD137 pathway, we observed a signiﬁcant increase in the
number of CD14+ and CD3 CD56+bright TNF-a and IFN-g-secreting
cells, demonstrating that the CD137 pathway inhibits cytokine
secretion from cells of the innate immunity. In agreement with
our ﬁndings, it was recently published that the consequences of
CD137–CD137L interaction between human NK cells and acute
myeloid leukemia blasts reduced NK-cell activation and IFN-g pro-
duction.28 On the other hand, we demonstrated that CD137:CD137L
interactions signiﬁcantly augmented CD3+TNF-a and IFN-g produ-
cing lymphocytes against M.tb Ag, denoting that CD137 signaling
promotes T-cell effector functions. Therefore, our ﬁndings show
opposite effects of the CD137/CD137L pathway on different cells of
the host immune response. Accordingly, it has been demonstrated that
whereas CD137 activation enhances T-cell responses,14 it inhibits
human NK-cell effector functions.28
Traditionally, CD137 was reported to be expressed and to induce
responses on CD8 T cells preferentially.14 In fact, in different models
of acute virus infection, the effect of CD137L appears to be limited
to CD8+ T lymphocytes.29,30 However, the CD137 costimulatory
pathway was also shown to affect CD4+ T-cell responses to viruses
that cause latent infections.23,31 In line with these reports, we have
demonstrated that, during the immune response to M. tuberculosis,
the blockade of CD137 enhances apoptosis and diminishes the
percentage of CD4+ and CD8+ IFN-g producing T cells.
CD137 has been established as a potent costimulatory molecule.12,32
Accordingly, we observed that signaling through CD137 regulated
apoptosis and proliferation of immune cells and promoted speciﬁc
lytic degranulation in TB patients. In line with our data, it was shown
that CD137L-deﬁcient mice displayed a loss of CTL-effector function
during latent murine gammaherpesvirus-68 infection.31 Thus, in
contrast to previous reports showing that signaling through CD137
did not contribute to Mycobacterium avium immunity,33 here we
demonstrate that the CD137 pathway participates in the immunity
against mycobacterial infection.
In the present study, we showed that CD137:CD137L interactions
may work differently on different cell populations, inhibiting or
increasing a particular cytokine secreted by a particular cell type.
Whereas the protective role of IFN-g in TB is well established,2 TNF-a
exhibits a very complex network of interactions and many of its
activities are still not fully understood.34 However, it is known that
TNF-a displays a main function in controlling M. tuberculosis infec-
tion, activating macrophages early during the immune response and
participating in granuloma formation.35,36 Conversely, excessive levels
of TNF-a may cause tissue damage in vivo,34 including hyperinﬂam-
mation, caseous necrosis and cachexia.37 Moreover, it has been
reported that a correlation exists between TNF-a levels and clinical
severity of human TB.38 Furthermore, the function of TNF-a in
humans is of clinical interest due to the association of anti-inﬂam-
matory TNF-blocking drugs with reactivation of latent TB.39,40
We demonstrated that CD137 signaling diminished TNF-a produc-
tion by monocytes (and NK cells) at early time points of M.tb
Ag stimulation. Therefore, since monocytes are the main source of
TNF-a, the CD137 pathway would be inhibiting TNF-a production
by these cells, thus preventing the down-regulation of the required
IFN-g produced by T cells.35,36 In fact, later during the immune
response and through the interaction between T cells and antigen
presenting cells, CD137:CD137L augmented IFN-g levels and T-cell
effector functions. Those levels of speciﬁc IFN-g against M.tb Ag
would be also regulated by SLAM, ICOS and PD-17,8,10 to reach the
necessary amounts of the cytokine in the microenvironment.
Contradictory information regarding the role of the CD137:
CD137L pathway on cytokine production during different bacterial
infections has been published.20,41 For example, it was reported that
CD137 /  and CD137L /  mice were resistant to septic shock induced
by lipopolysaccharide (LPS).42 In contrast, stimulation through CD137
was demonstrated to protect mice from Listeria monocytogenes
sepsis-induced death.20 Moreover, it has been proposed that CD137
would have opposite functions in Gram-negative and Gram-positive
bacterial infections.42 Therefore, CD137 would have different roles
depending on the infecting bacterial species. Accordingly, here we
demonstrated that CD137/CD137L signaling displayed a speciﬁc role
against M. tuberculosis infection. In particular, we propose that CD137/
CD137L signaling on innate cells would operate as a negative feedback
regulatory mechanism to avoid an exacerbated inﬂammatory response
and to limit collateral damage during the immune response to
M. tuberculosis,b u ta l l o w i n gt h ep r e s e n c eo fe n o u g hl e v e l so fc y t o k i n e s
to control the infection. However, later during the immune response,
CD137 signaling would stimulate the production of IFN-g by T cells to
reach the required protective levels to ﬁght M. tuberculosis.T h e r e f o r e ,
our results suggest that the CD137 pathway regulates the levels of
IFN-g and TNF-a required by the host to combat M. tuberculosis at
different steps of the immune response. Therefore, the present ﬁndings
support a dual role of the CD137/CD137L pathway in mediating both
stimulatory and inhibitory signaling activities during human infection.
Figure 5 Role of CD137 pathway on lytic degranulation against M. tuberculosis. PBMC from TB patients and HD were stimulated with M.tb Ag in the
presence or absence of blocking anti-CD137mAb. After 5 days, the expression of CD107a/b was determined on CD3+CD8+ T cells by ﬂow cytometry. (a)
Each bar represents the mean±s.e.m. of the percentage of CD3+CD8+CD107a/b+ cells (seven individuals per group). (b) A representative TB patient out of
seven is shown. Isotype controls (inset) are also shown. **Po0.01; *Po0.05 Wilcoxon rank sum test. wPo0.05 Mann–Whitney U-test.
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Immunology and Cell BiologyAnti-CD137 antibodies are powerful immune modulators and have
shown promise in therapeutic mouse models of cancer, viral disease
and autoimmunity. Moreover, phase I and II clinical trials using
anti-CD137 therapy for advanced cancers are underway.43 By using
blocking mAbs, we demonstrated that CD137/CD137L pathway
regulates the immune response during active TB. However, caution
must be used in designing ways to manipulate CD137 in human
therapy, given that agonistic anti-CD137 antibodies can cause severe
immune system abnormalities13,43 and considering that the
CD137:CD137L pathway may operate differently on distinct cells
from the innate and adaptive immune response.
METHODS
Study subjects
Healthy adults (n¼40) with no history of TB participated in the study. All
participants had received Bacillus Calmette-Gue ´rin vaccination at birth. A
previous established M. tuberculosis-speciﬁc IFN-g assay (Quantiferon TB Gold
test, Cellestis Inc., Valencia, CA, USA) was used to differentiate individuals with
LTBl (latent TB infection) from true HD without LTBI. Subjects with LTBI were
excluded from the study. HIV-uninfected patients (n¼40) with active TB were
evaluated at the Hospital Mun ˜iz (Buenos Aires, Argentina). The diagnosis of
TB was established based on clinical and radiological data together with
the identiﬁcation of acid-fast bacilli (AFB) in sputum (+/ ): 36/4. The ages
of each group (median (interquartile range) were HD, 34.3 (22–58); and
Figure 6 Effect of CD137:CD137L pathway on proliferation and T-cell apoptosis against M. tuberculosis.( a) PBMC from TB patients and HD were cultured
i nt h ep r e s e n c eo fM.tb Ag ±CD137 or CD137L blocking mAbs. After 5 days, cells were pulsed with TdR (1mCi per well), harvested 16h later, and [3H]TdR
incorporation was measured in a liquid scintillation counter. Each bar represents the mean±s.e.m. from each group (nine individuals per group). (b, c)
PBMC from TB patients were cultured in the presence of M.tb ±CD137 or CD137L blocking mAbs. After 5 days, the cells were stained with Annexin V and
PI together with CD3. The percentage of apoptotic/necrotic cells was determined by ﬂow cytometry by gating on CD3+ T cells. (b) Data of seven independent
experiments are shown (mean±s.e.m.). P-values were calculated using the Wilcoxon rank sum test by comparing the mean of the percentage of Annexin V+
or Annexin V+IP  T cells cultured with M.tb versus media, M.tb+anti-CD137 or M.tb + anti-CD137L. (c) The number of apoptotic/necrotic cells was also
determined on CD3+CD4+ and CD3+CD8+ cells. A representative dot plot out of seven TB patients analyzed is shown. **Po0.01; *Po0.05 Wilcoxon rank
sum test. wPo0.05 Mann–Whitney U-test.
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Immunology and Cell BiologyTB, 32.2 (18–63). The male:female ratio of each group was HD, 28:12;
TB, 26:14.
All participating patients had received o1 week of anti-TB therapy.
Peripheral blood samples were collected in heparinized tubes from all indivi-
duals after receiving informed consent. The local ethical committee approved
all the studies performed.
Antigen
In vitro stimulation of cells throughout the present study was performed with a
cell lysate from the virulent M. tuberculosis H37Rv strain, prepared by probe
sonication. In brief, the reagent was obtained generously through the NIH
Biodefense and Emerging Infections Research Resources Repository, NIAID,
NIH: M. tuberculosis, Strain H37Rv, whole-cell lysate, NR-14822. Afterwards,
probe sonication was applied to the cell lysate following the standard
methods. The preparation was ﬁnally suspended in free pyrogen phosphate-
buffered saline and adjusted to a concentration of 1 108bacteriaml–1 (optical
density (OD)600nm¼1). The antigen preparation is indicated as ‘M. tuberculosis
antigen (M.tb Ag)’ throughout the manuscript.
Culture conditions
PBMC were isolated by density gradient centrifugation on Ficoll-Paque
(Amersham Biosciences, Buckingham, UK), resuspended in supplemented
RPMI1640 (Gibco, Carlsbad, CA, USA) and cultured (1 106cellsml–1)i n
ﬂat-bottom 24-welll or 96-well plates (Greiner Bio-One, Frickenhausen,
Germany). In different experiments, cells were incubated in the presence/
absence of M.tb Ag (10mgml –1). At different times, CD137 and CD137L
expression was determined by ﬂow cytometry (see below). For blocking
experiments, cells were incubated 30min with blocking mAbs (BD, Bergen
County, NJ, USA) against CD137 (5mgml –1, 4B4-1), CD137L (5mgml –1,
C65–485), or isotype control. Then, cells were stimulated with or without
M.tb Ag. After 16h, 4 or 5 days, the percentage of IFN-g or TNF-a-secreting
cells, lytic degranulation and apoptosis were determined by ﬂow cytometry
(see below). Cells cultured with M.tb Ag±blocking mAbs against CD137 or
CD137L for 5 days were also pulsed with [3H]TdR (1mCi per well), harvested
1 6 hl a t e ra n d[ 3H]TdR incorporation was measured in a liquid scintillation
counter. In separated experiments, mAbs anti-CD137 or anti-CD137L were
added to cells with or without the speciﬁc Ag. After 16, 48h or 5 days, IFN-g
and TNF-a production was evaluated by ELISA (enzyme-linked immuno-
sorbent assay) following the manufacturer’s instructions (eBioscience,
San Diego, CA, USA).
Flow cytometry
In different experiments, PBMC were cultured with M.tb. Ag±CD137 or
CD137L blocking mAbs and stained for CD3, CD4, CD8, CD56, CD14, CD137
(0.5mgml –1, 4B4-1) and CD137L (0.5mgml –1, C65-485) expression using
speciﬁc mAbs (BD). Intracellular cytokine staining was also performed to
determine IFN-g and TNF-a (eBioscience) production at the single-cell level as
reported.44 Negative control samples were incubated with irrelevant, isotype-
matched mAbs in parallel with experimental samples. Samples were analyzed
on a FACS ARIA II Cell sorter (BD).
Lytic degranulation
CD107a/b lysosome-associated membrane protein-1/2 expression was used
to measure CD8+ T lymphocyte degranulation, as previously described.45
Negative control samples were incubated with irrelevant, isotype-matched
mAbs in parallel with all experimental samples.
Annexin V and PI staining
PBMC were cultured with M.tb. Ag±CD137/CD137L blocking mAbs. After
5 days, the percentage of apoptotic/necrotic CD3+,C D 3 +CD4+ or CD3+CD8+
cells was determined using the Annexin V-FITC Apoptosis Detection Kit I (BD)
following the instructions of the manufacturer.
Statistical analysis
Statistical analysis was performed using the non-parametric Wilcoxon rank
sum test for paired samples and the Mann–Whitney U-test for non-paired
samples. Values of Po0.05 were considered signiﬁcant.
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